Aptivus(R) (tipranavir) Capsules Granted Full Approval By The U.S. FDA
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted full (traditional) approval of Aptivus(R) (tipranavir) capsules. The FDA granted accelerated approval to APTIVUS in June 2005; accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses.
